Phase Ib Study of TU7710: Safety, Pharmacokinetics, and Pharmacodynamics in Patients with Hemophilia A or B

The primary objective of this study is to evaluate the **safety**, pharmacokinetics, and pharmacodynamics of TU7710 in patients diagnosed with **Hemophilia A** or **B**. This is clinically relevant as it aims to assess the potential therapeutic benefits and risks associated with TU7710, which could inform treatment strategies and improve patient outcomes in managing **Hemophilia**. No secondary objectives are provided.

The clinical trial focuses on **hemophilia** and involves a study population consisting exclusively of male participants. The age range of the participants falls within categories 3 and 4, which typically correspond to adults and older adults. The trial does not include a vulnerable population, and the sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. The sponsor has not provided key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of TU7710 in patients diagnosed with **hemophilia** A or B. This study is structured as a Phase Ib trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is scheduled to commence recruitment on June 15, 2024, and is anticipated to conclude by December 31, 2025, providing a comprehensive assessment over this period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are designed to monitor the participants' health status, assess the drug's effects, and ensure adherence to the study protocol. The sequence and frequency of these visits will be determined by the study protocol to ensure consistent data collection and participant safety.

The end-of-study visit marks the final assessment point, where comprehensive evaluations will be conducted to gather final data on the drug's impact and any long-term effects. The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit, unless specific conditions necessitate early termination. Such conditions may include adverse reactions, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to uphold scientific rigor and participant safety throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on June 15, 2024, with an estimated completion date of December 31, 2025. Efficacy assessments will be conducted at predetermined intervals throughout the trial period. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and tools for measurement, collection, and analysis, are not detailed in the provided data. The trial will adhere to rigorous standards typical of Phase 3 studies to ensure the reliability and validity of the efficacy outcomes.